Literature DB >> 10676748

Medulloblastoma.

A T Reddy1, R J Packer.   

Abstract

The utilization of multi-modal therapy in the treatment of medulloblastoma has improved survival rates and overall outcome. Recent large clinical trials have supported the use of radiation and chemotherapy as adjuvant treatment. Treatment advances have been made despite a poor understanding of the biological underpinnings of medulloblastoma. Current laboratory investigations are shedding light on the oncogenesis of medulloblastoma and may lead to improved treatments.

Entities:  

Mesh：

Year:  1999        PMID： 10676748     DOI： 10.1097/00019052-199912000-00004

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN： 1350-7540            Impact factor:   5.710


  7 in total

1.  Characterization of signaling function and expression of HLA class I molecules in medulloblastoma.

Authors:  Courtney Smith; Mariarita Santi; Elisabeth J Rushing; Robert Cornelison; Tobey J MacDonald; Stanislav Vukmanovic
Journal:  J Neurooncol       Date:  2010-09-02       Impact factor: 4.130

2.  An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Authors:  Fadila Guessous; Ying Zhang; Charles diPierro; Lukasz Marcinkiewicz; Jann Sarkaria; David Schiff; Sean Buchanan; Roger Abounader
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

3.  Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers.

Authors:  Alvin T Kho; Qing Zhao; Zhaohui Cai; Atul J Butte; John Y H Kim; Scott L Pomeroy; David H Rowitch; Isaac S Kohane
Journal:  Genes Dev       Date:  2004-03-15       Impact factor: 11.361

4.  Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model.

Authors:  David I Sandberg; Kenneth M Crandall; Tulay Koru-Sengul; Kyle R Padgett; John Landrum; Darwin Babino; Carol K Petito; Juan Solano; Manuel Gonzalez-Brito; John W Kuluz
Journal:  J Neurooncol       Date:  2009-08-18       Impact factor: 4.130

5.  Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression.

Authors:  Andrey Korshunov; Marina Savostikova; Sergey Ozerov
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

Review 6.  A mouse model for medulloblastoma and basal cell nevus syndrome.

Authors:  R B Corcoran; M P Scott
Journal:  J Neurooncol       Date:  2001-07       Impact factor: 4.130

7.  Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5.

Authors:  Yang Li; Xing Fan; C Rory Goodwin; John Laterra; Shuli Xia
Journal:  BMC Cancer       Date:  2008-11-07       Impact factor: 4.430
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.